RESUMO
The authors present the results of domestic clinical trials on the efficacy and safety of mexidol in patients with cerebrovascular disorders including ischemic stroke (IS). The use of mexidol is associated with complete and rapid regression of the focal neurological deficit. Mexidol is well tolerated with no significant side-effects. The drug is recommended for enteral and parenteral administration in patients with IS.
Assuntos
Isquemia Encefálica , Fármacos Neuroprotetores , Acidente Vascular Cerebral , Isquemia Encefálica/prevenção & controle , Transtornos Cerebrovasculares/prevenção & controle , Humanos , Fármacos Neuroprotetores/uso terapêutico , Acidente Vascular Cerebral/prevenção & controleRESUMO
High level of glucose in the blood in hypoxic-ischemic states is one of the main factors that complicates the degree of brain damage. An increased level of reactive oxygen species and impaired functioning of the endogenous antioxidant system are the consequences of the hyperglycemic-ischemic condition. Medical treatment is necessary to compensate for the development of cerebrovascular disorders in ischemia comorbid to diabetes mellitus. The use of antioxidants (2-ethyl-6-methyl-3-hydroxypyridine succinate) is the most therapeutically effective.